NoNO’s core science is published, well-established and reproducible. Initially discovered by NoNO, PSD-95 inhibition has now been validated both internally and externally by numerous independent research groups worldwide with preclinical results in stroke, stroke recovery, Alzheimer’s, anxiety, epilepsy, retinal ischemia and traumatic brain injury. Our core technology is wholly owned and supported by a portfolio of more than 300 granted patents globally.
NoNO’s pipeline is built around its lead asset nerinetide, a first-in-class peptide inhibitor of PSD-95 (postsynaptic density protein 95) which crosses the blood brain barrier and binds PSD-95 and the enzyme neuronal nitric oxide synthase (nNOS) to mediate its effects. PSD-95 protein is the essential linker between NMDA glutamate receptors and nNOS responsible for generating the damaging reactive species nitric oxide following both ischemic and mechanical stretch injuries. Nerinetide and its analogs disconnect this link, protecting neurons in the acute injury phase and promoting neural plasticity for functional restoration in the recovery phase.